South Wales, Nov. 20 -- UK Intellectual Property Office has received a patent application (GB2611155.9) with the title ‘ADAPTIVE MELANOPSIN-TARGETED SAD THERAPY: LOCATION-ADAPTIVE DOSE-RATE EQUIVALENCE METHOD WITH MELANOPSIN-WEIGHTED IRRADIANCE COMPUTATION, BIOFEEDBACK-RESPONSIVE DOSING, MULTI-DEVICE DOSE AGGREGATION, AND WEARABLE SPECTACLE DELIVERY SYSTEM.’
Here are the other details related to the patent application:
Status: Filed
Filing Date: 2026-05-13
Owner(s): SENSIO BIOLABS LTD
Disclaimer: Curated by HT Syndication.